文献速递肿瘤 PET/CT

定量18F-FDG-PET影像组学分析在头颈部鳞状细胞癌患者中的预测价值

Predictive value of quantitative 18F-FDG-PET radiomics analysis in patients with head and neck squamous cell carcinoma.
PubMed 文献 · EJNMMI Res · 2020-09-07

本研究旨在识别预测头颈部鳞状细胞癌放化疗后复发、远处转移和总生存的18F-FDG-PET影像组学特征。2012至2018年间,103例回顾性患者(训练队列)和71例连续纳入患者(验证队列)接受了18F-FDG-PET/CT检查,提取434个影像组学特征并经冗余过滤后投影为结局无关的元特征(因子)。将因子与18F-FDG-PET参数及临床参数结合进行多变量生存回归并验证,构建了临床适用的风险分层。

要点

  • 复发预测最准确的是结合HPV状态、SUVmean、SUVpeak及因子3、4、6(CI=0.645)。
  • 远处转移预测最准确的是代谢活跃肿瘤体积(MATV)(CI=0.627)。
  • 总生存预测最准确的是结合HPV状态、SUVmean、SUVmax及因子1、5(CI=0.764)。

核心结论

  • 结合HPV状态、一阶18F-FDG-PET参数和互补的影像组学因子对时间-事件预测最为准确。
  • 影像组学因子可能捕捉并保留预测性表型特异性肿瘤特征及相互作用,从而实现个体化风险分层并优化个体化癌症治疗。

研究设计与样本

  • 2012至2018年间,103例回顾性患者(训练队列)和71例连续纳入患者(验证队列)接受了18F-FDG-PET/CT成像。
  • 提取434个影像组学特征,经冗余过滤后投影为结局无关的元特征(因子)。
  • 评估临床参数、一阶18F-FDG-PET参数(如SUVmean)与因子之间的相关性。
  • 将因子与18F-FDG-PET参数及临床参数结合进行多变量生存回归并验证,构建临床适用的风险分层。

主要发现

  • 基于103例患者保留的124个影像组学特征,构建了8个因子。
  • 复发预测最准确的是结合HPV状态、SUVmean、SUVpeak、因子3(直方图梯度与长游程低灰度强调)、因子4(体积差、粗糙度与灰度非均匀性)和因子6(直方图变异系数)(CI=0.645)。
  • 远处转移预测最准确的是评估代谢活跃肿瘤体积(MATV)(CI=0.627)。
  • 总生存预测最准确的是使用HPV状态、SUVmean、SUVmax、因子1(最短轴长度、非均匀性、高灰度级高依赖性)和因子5(非球形度、长轴长度、逆紧凑度与逆平坦度)(CI=0.764)。

关键数值与推荐

  • 复发预测模型:HPV状态、SUVmean、SUVpeak、因子3、因子4、因子6(CI=0.645)。
  • 远处转移预测模型:MATV(CI=0.627)。
  • 总生存预测模型:HPV状态、SUVmean、SUVmax、因子1、因子5(CI=0.764)。

临床怎么用

  • 可将HPV状态、一阶18F-FDG-PET参数与影像组学因子结合用于头颈部鳞状细胞癌放化疗后的复发、远处转移和总生存预测。
  • 基于所构建的风险分层可实现个体化风险分层,辅助优化个体化癌症治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiomics is aimed at image-based tumor phenotyping, enabling application within clinical-decision-support-systems to improve diagnostic accuracy and allow for personalized treatment. The purpose was to identify predictive 18-fluor-fluoro-2-deoxyglucose (18F-FDG) positron-emission tomography (PET) radiomic features to predict recurrence, distant metastasis, and overall survival in patients with head and neck squamous cell carcinoma treated with chemoradiotherapy. METHODS: Between 2012 and 2018, 103 retrospectively (training cohort) and 71 consecutively included patients (validation cohort) underwent 18F-FDG-PET/CT imaging. The 434 extracted radiomic features were subjected, after redundancy filtering, to a projection resulting in outcome-independent meta-features (factors). Correlations between clinical, first-order 18F-FDG-PET parameters (e.g., SUVmean), and factors were assessed. Factors were combined with 18F-FDG-PET and clinical parameters in a multivariable survival regression and validated. A clinically applicable risk-stratification was constructed for patients' outcome. RESULTS: Based on 124 retained radiomic features from 103 patients, 8 factors were constructed. Recurrence prediction was significantly most accurate by combining HPV-status, SUVmean, SUVpeak, factor 3 (histogram gradient and long-run-low-grey-level-emphasis), factor 4 (volume-difference, coarseness, and grey-level-non-uniformity), and factor 6 (histogram variation coefficient) (CI = 0.645). Distant metastasis prediction was most accurate assessing metabolic-active tumor volume (MATV)(CI = 0.627). Overall survival prediction was most accurate using HPV-status, SUVmean, SUVmax, factor 1 (least-axis-length, non-uniformity, high-dependence-of-high grey-levels), and factor 5 (aspherity, major-axis-length, inversed-compactness and, inversed-flatness) (CI = 0.764). CONCLUSIONS: Combining HPV-status, first-order 18F-FDG-PET parameters, and complementary radiomic factors was most accurate for time-to-event prediction. Predictive phenotype-specific tumor characteristics and interactions might be captured and retained using radiomic factors, which allows for personalized risk stratification and optimizing personalized cancer care. TRIAL REGISTRATION: Trial NL3946 (NTR4111), local ethics commission reference: Prediction 2013.191 and 2016.498. Registered 7 August 2013, https://www.trialregister.nl/trial/3946.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Martens RM, Koopman T, Noij DP, et al. Predictive value of quantitative 18F-FDG-PET radiomics analysis in patients with head and neck squamous cell carcinoma. EJNMMI Res. 2020. PMID: 32894373. doi:10.1186/s13550-020-00686-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。